The influence of comorbidity on the severity of COVID-19 disease: systematic review and analysis

Shortened title: Comorbidity effect on the severity of COVID-19

Nazar Zaki[1], Elfadil A. Mohamed[2] Sahar Ibrahim[3] and Gulfaraz Khan[4]

[1]Big Data Analytics Center (BiDAC), Department of Computer Science and Software Engineering, College of Information Technology, United Arab Emirates Univerity

[2]College of Engineering and Information Technology, Ajman University, United Arab Emirates Univerity

[3]Weldon School of Biomedical Engineering, Purdue University, US

[4]Department of Medical Microbiology and Immunology, College of Medicine and Heath Sciences, United Arab Emirates Univerity

Corresponding Author:
Nazar Zaki
Email: nzaki@uaeu.ac.ae
Phone: 00971 507332135

Abstract

A novel form of coronavirus disease (SARS-CoV-2) has spread rapidly across the world. This disease, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease is of considerable importance. This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19. The meta-analysis incorporated seven studies covering 4101 COVID-19 patients from Chinese hospitals who had their diagnosis confirmed through laboratory testing. The findings demonstrate that the most common comorbidities with the disease were COPD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006), cardiovascular disease (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), coronary heart disease (5.52%, OR 2.97 [95% CI: 1.99-4.45], p <0.0001), diabetes (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), and hypertension (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001). No significant associations were found for disease severity with the comorbidities of kidney disease, liver disease, or cancer. The most frequently exhibited clinical symptoms were fever (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia/fatigue (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), respiratory failure/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002), diarrhea (11.21%) and chest tightness/pain (16.82%, OR 2.17, 95% CI: 1.40-3.36, p = 0.0006). Meta-analysis also revealed that neither the duration of the incubation period nor current smoking status associated with disease severity.

Keywords: *meta-analysis, cardiovascular disease, hypertension, diabetes, SARS-CoV-2, COVID-19*

Introduction

The 2019/2020 emergence of the novel COVID-19 disease and its swift global expansion represents a health emergency for all of humanity. This novel virus, which causes severe acute respiratory disease, is believed to be a member of the same family of coronaviruses as the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) [1]. Unprecedented efforts are currently being made to identify the risk factors that increase the severity of the disease. The World Health Organisation (WHO) has suggested that patients with certain medical conditions and elderly people are at greatest risk of developing more severe disease [2]. As of June 13, 2020, over 7.6 million people have been infected and 425,800 have died from the disease. The majority of deaths are thought to have associations with the existence of one or more comorbidity. In general, it is believed that patients with compromised immune system are especially at high risk [3]. A number of researchers have examined the clinical/epidemiological characteristics of patients suffering COVID-19, but there has been insufficient investigation regarding mortality risk factors [4]. The identification of the principal risk factors and employing appropriate clinical interventions to mitigate them could save numerous lives. Numerous studies indicate that kidney disease, COPD, coronary heart disease, liver disease, cardiovascular disease, diabetes mellitus, and hypertension are amongst the most important risk factors for COVID-109. This paper will undertake a systemic review of the literature to illuminate the way in which the impact of the COVID-19 virus can be made more severe by the existence of such comorbidities and extant conditions.

Materials/methodology

Eligibility criteria

This research looked for all relevant published articles between the dates of December 1, 2019, and May 20, 2020, i.e. those that were related to comorbidity and its influence on the severity of COVID-19. Papers were excluded if they were related to the adult patients, if they were not written in English, if they had not been peer reviewed, or if they were not original (e.g. reviews, editorials, letters, commentaries, or duplications). Papers mainly focused on severe vs nonsevere groups of patients were considered. Severe group are those who develop severe illnesses. These cases are more likely to result in ICU admission or death.

Search strategies/data extraction

A search was undertaken on the COVID-19 Open Research Dataset (CORD-19), which is regularly updated [5]. This dataset contains more than 128,000 scholarly articles; 59,000 of these articles have full text that relates to coronavirus, SARS-CoV-2, and COVID-19. A search engine running over the BM25 search index was created so that all articles in this dataset could be screened [6]. The BM25 retrieval function creates a document ranking for a dataset on the basis of whether or not searched terms appear in the documents, no matter how proximate they may be to each other. Indexing of the papers occurs through simple application of preprocessing functions that clean and tokenize abstracts. Having indexed all documents, document vectors were created through loading optimized cached JSON tokens and subsequent application of a document similarity index founded on Annoy [7]. Annoy is a C++ library that has Python bindings for searching for documents within a space that make a close match to a specific query. This is an efficient and simple process as it creates substantial read-only file-based data structures used with memory mapping allowing several processes to work with identical data. More detail on this implantation can be found at HTTP://github.com/dgunning/cord19.

Articles were then filtered employing questions and keywords such as "Effects of diabetes on COVID/normal coronavirus/SARS-CoV-2/nCoV/COVID-19 disease severity?" This search was undertaken for every comorbidity under consideration in this research (Figure 1).

```
research_papers.search('Effects of diabetes mellitus on COVID-19 diseases severity')
```

COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
3 weeks ago   Link   fe8f7tk1

Background and aims Diabetes mellitus is associated with poor prognosis in patients with COVID-19. On the other hand, COVID-19 contributes to worsening of dysglycemia in people with diabetes mellitus over and above that contributed by stress hyperglycemia. Herein, we have reviewed the two-way interactions between COVID-19 and diabetes mellitus. Results Compromised innate immunity, pro-inflammatory cytokine milieu, reduced expression of ACE2 and use of renin-angiotensin-aldosterone system antagon...

Pal, Rimesh; Bhadada, Sanjay K.

Use Stones from Another Mountain to Polish One's Jade: Learn from MERS Studies toexplore potential mechanisms underlying the effect of diabetes mellitus on COVID-19
4 months ago   Link   eqewn6j4

Epidemiology studies suggest that comorbid diabetes may have negative impact on the progression and severity of the coronavirus disease 2019 (COVID-19), which first occurred in Wuhan However, the exact mechanism remains unclear A recent study on another type of coronavirus infection, Middle East Respiratory Syndrome (MERS), investigated its relationship with diabetes This essay aims to give a brief introduction to this report and related studies, and to propose suggestions on what we can learn f...

YANG, Sijue

Figure 1: Example of retrieved artcles from a search for diabetes mellitus

Additionally, an independent search was undertaken by two researchers (NZ and EA), who systematically examined the PubMed, Europe PMC, and Google Scholar databases. These searches obtained information regarding name of author, year of publication, publication name, age, gender, severity/non-severity of the disease, and the presence of any clinical symptoms, i.e. chest tightness/pain, respiratory failure/ARDS, dyspnoea, myalgia/fatigue, diarrhea, cough, or fever. Where either vital or non-vital information was absent, requirement for admission to ICU was employed to indicate how severe the disease was.

The articles that remained underwent independent screening once more by the two researchers (NZ and EA). Any disagreement was settled either by consensus or by the casting vote of a third researcher (SI). Research was completed on May 20th, 2020; the stages of this systemic literature search are illustrated in Figure 2.

Data analysis

Meta-analysis was undertaken employing a python library "meta". Odds ratios (ORs) were employed for describing the risk factors of various comorbidities for patients with severe disease compared to those with mild disease. Due to internal and external heterogeneities, random effect modeling was employed for estimation of average effects and their precision, offering a more cautious estimate regarding the 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I^2 statistic.

Machine learning techniques based on regression, e.g. support vector machine (SVM) [8], linear regression, multi-perceptron [9], random forest [10], and attribute selection techniques such as Wrapper Subset Evaluator [11], Correlation Ranking Filter, and ReliefF Ranking Filter [12] as implemented in WEKA [13] were employed for determination of how useful and significant different elements were in terms of the prediction of levels of severe instances of COVID-19. Consideration was only given to the conditions kidney disease, coronary heart disease, COPD, liver disease, cardiovascular disease, cancer, diabetes mellitus, and hypertension. Clinical symptoms that were added to consideration as independent attributes were diarrhea, chest tightness/pain, respiratory failure, dyspnoea, fatigue, coughing, and fever, incubation period, current smoking status, and patient gender.

Fig. 2: Flowchart showing research inclusions/exclusions of articles

Results

303 articles were found through the search of Europe PMC, PubMed, and the COVID-19 database; 110 of these were excised as they were duplicates. In total 74 text articles were examined to see if they were eligible once 125 articles had been removed due to the fact that they were not English-language articles, did not have a full text, were duplicates, were editorials, were letters, were reviews, were irrelevant, or not peer-reviewed. Ultimately, the meta-analysis group comprised 12 articles that met all quantitative and qualitative standards.

As Table 1 shows, the median age for severe cases was 58.8 years, and for non-severe cases 48.5 years; 53.55% of patients were male. The meta-analysis demonstrated that the highest levels of comorbidity were with hypertension (22.07%), diabetes (11.34%), cardiovascular disease (10.76%), liver disease (6.31%), coronary heart disease (5.52%), kidney disease (3.82%), and COPD (2.53%). In terms of clinical symptoms, the most common were fever (74.52%), cough (62.15%), myalgia/fatigue (38.77%), dyspnoea (33.9%) respiratory failure/ARDS (20.6%), diarrhea (11.21%) and chest tightness/pain (16.82%). Meta-analysis indicated that neither length of incubation period nor current smoking status had any associations with disease severity.

Figure 3 (A-H) shows an analysis of comorbidities comparing the severe and nonsevere groups. Meta-analysis indicated that disease severity had associations with diabetes (OR 2.27, [95% CI: 1.46-3.53], p = 0.0003; I^2: 62%), hypertension (OR 2.43 [95% CI: 1.71-3.45], p < 0.0001); I^2:62%), coronary heart disease (OR 2.97 [95% CI: 1.99-4.45], p < 0.0001; I^2: 0%), cardiovascular disease (OR 2.89 [95% CI: 1.90-4.40], p < 0.0001, I2:38%), and COPD (OR 3.24 [95% CI: 1.66-6.32], p = 0.0006; I2: 0%). No significant correlation was found between disease severity and kidney or liver disease. The I^2 test for heterogeneity ranged between nought percent and 62%, indicating a fair level of statistical heterogeneity. With COPD and coronary heart disease, I^2 was equal to 0%, meaning no heterogeneity can be found, making this research adequately homogenous.

Figure 4 (a-H) indicates that associations for COVID-19 severity were as follows: with respiratory failure/ ARDS (OR 11.46, 95% CI: 3.24-40.56, p = 0.0002; I: 89%), fever (OR 1.37, 95% CI: 1.01-1.86, p = 0.04; I: 40%), myalgia/fatigue (OR 1.31, 95% CI: 1.11-1.55, p = 0.0018; I: 0%), dyspnea (OR 3.61, 95% CI: 2.57-5.06, p = <0.0001; I: 43%), and chest tightness/pain (OR 2.17, 95% CI: 1.40-3.36, p = 0.0006; I: 71%).

Table 1: Summary of research used for meta-analysis including characteristics of severe/non-severe groups with a number of common comorbidities and clinical conditions.

		Liu, W., et al. CMJ [14]	Huang, C., et al. LANCET [15]	Wang, D., et al. JAMA [16]	Tian, J., et al. LANCET [17]	Zhang, J., et al. ALLERGY [18]	Guan, W., et al. NEJM [19]	Zhang, J. et al., CMI [20]	Li, X., JACI [21]	Zheng, F., ERMPS [22]	Feng Y. et al., AIRCCM [23]	Shi, Y., CC [24]	Huang R. et al., PLOS NTD [25]						
Basic Information																			
Samples		78	41	138	232	140	1,099	569	548	161	406	487	202	Total = 4,101					
Median Age	S[a]	66	49	66	64	64	52	59.6	65	57	58	56	49	Average = 58.8					
	NS[b]	37	49	51	63	51.5	45	49.1	56	40	51	45	44	Average = 48.5					
Male	S	S	7	11	22	81	33	100	149	153	14	33	36	Total = 656					
	NS	NS	32	19	53	38	38	540	116	126	66	190	223	Total = 1,540					
Female	S	S	4	2	14	67	25	73	166	116	16	21	13	Total = 523					
	NS	NS	35	9	49	46	44	386	138	153	65	162	215	Total = 1,382					
Total	S	11	13	36	148	58	173	315	269	30	54	49	23	Total = 1,179					
	NS	67	28	102	84	82	926	254	279	131	352	438	179	Total = 2,922					
Comorbidities														OR	95% CI	P-value[c]	I²	P-value[d]	H
Diabetes	S	2	1	8	33	8	28	NA[e]	52	2	11	7	8	2.27	1.46-3.53	0.0003	62%	< 0.01	1.63
	NS	3	7	6	22	9	53	NA	31	5	32	22	11						
Hypertension	S	2	2	21	68	22	41	NA	104	12	15	26	2	2.43	1.71-3.45	< 0.0001	62%	< 0.01	1.62
	NS	6	4	22	28	20	124	NA	62	10	73	73	27						
Coronary Heart Disease	S	1	1	9	17	4	10	NA	28	2	NA	2	NA	2.97	1.99-4.45	< 0.0001	0%	= 0.68	1.00
	NS	1	0	11	5	3	17	NA	6	2	NA	20	NA						
Cancer	S	2	NA	4	148	NA	3	NA	NA	NA	NA	NA	NA	2.65	1.12-6.29	0.0272	0%	= 0.57	1.00
	NS	2	NA	6	84	NA	7	NA	NA	NA	NA	NA	NA						
Liver Disease	S	NA	0	0	NA	4	NA	12	62	0	NA	NA	0	0.66	0.22-1.97	0.4604	78%	< 0.01	2.13
	NS	NA	1	4	NA	4	NA	41	44	4	NA	NA	4						
COPD	S	1	NA	3	2	2	NA	NA	13	2	3	NA	NA	3.24	1.66-6.32	0.0006	0%	= 0.89	1.00
	NS	1	NA	1	1	0	NA	NA	4	4	8	NA	NA						
Kidney Disease	S	NA	0	2	4	NA	5	32	6	NA	NA	NA	NA	2.24	1.01-4.99	0.0476	38%	= 0.15	1.27
	NS	NA	3	2	2	NA	1	12	4	NA	NA	NA	NA						
Cardiovascular Disease	S	NA	3	9	6	NA	NA	82	94	NA	5	4	1	2.89	1.90-4.40	< 0.0001	38%	= 0.12	1.27
	NS	NA	3	11	3	NA	NA	33	25	NA	21	7	4						
Symptoms																			
Cough	S	4	11	21	86	45	122	202	203	21	28	NA	17	1.25	0.97-1.60	0.0823	44%	= 0.05	1.34
	NS	30	20	61	33	45	623	155	212	80	220	NA	103						
Respiratory/ ARDS	S	6	8	22	NA	NA	NA	23	183	NA	NA	NA	9	11.46	3.24-40.56	0.0002	89%	<0.01	3.06
	NS	14	4	5	NA	NA	NA	13	27	NA	NA	NA	0						
Fever	S	4	13	36	99	51	82	257	228	29	49	NA	20	1.37	1.01-1.86	0.0400	40%	= 0.08	1.29
	NS	25	27	100	51	59	391	198	248	93	277	NA	136						
Myalgia/Fatigue	S	NA	7	29	39	39	69	110	130	15	4	NA	7	1.31	1.11-1.55	0.0018	0%	= 0.50	1.00
	NS	NA	11	67	13	51	350	63	128	49	38	NA	37						
Dyspnea	S	NA	12	23	52	24	NA	94	198	9	NA	NA	NA	3.61	2.57-5.06	< 0.0001	43%	= 0.10	1.00
	NS	NA	10	20	11	20	NA	37	112	14	NA	NA	NA						
Diarrhea	S	NA	0	6	18	9	10	36	85	1	NA	NA	0	1.11	0.87-1.42	0.4052	0%	= 0.44	1.00
	NS	NA	1	8	8	9	32	25	94	16	NA	NA	13						
Chest Tightness/Pain	S	NA	NA	NA	23	24	65	91	16	NA	14	NA	6	2.17	1.40-3.36	0.0006	71%	< 0.01	1.86
	NS	NA	NA	NA	6	20	140	37	25	NA	50	NA	13						
Other Information																			
Incubation Period	S	NA	8	NA	NA	7	4	NA	10	6	NA	NA	NA	2.70	1.33-5.47	0.0058	43%	= 0.13	1.33
	NS	NA	6.5	NA	NA	8	4	NA	8	6	NA	NA	NA						
Smoking	S	3	0	NA	NA	2	29	NA	18	NA	7	6	2	1.45	0.93-2.27	0.1028	34%	= 0.16	1.23
	NS	2	3	NA	NA	0	108	NA	23	NA	27	37	14						
Deaths	S	NA	5	NA	38	NA	14	25	87	NA	3	NA	0	4.11	0.12-135.37	0.4277	98%	< 0.01	7.77
	NS	NA	1	NA	8	NA	1	229	3	NA	6	NA	0						

[a] S: Severe, [b] NS: Non-severe, [c] P-Value based on the random-effects model, [d] P-Value based on the test of heterogeneity, [e] NA: Information not available.

Fig. 3. Forest-plots indicate that the comorbidities diabetes mellitus, hypertension, coronary heart disease, and cardiovascular disease had associations with composite poor outcomes, severe COVID-19, and ICU care requirements. This is not true of cancer, liver disease, and kidney disease patients.

Fig. 4. Forest-plots indicate that clinical conditions like respiratory failure/ ARDS, dyspnea, and chest tightness/pain have associations with higher composite poor outcomes, severe COVID-19, and ICU care requirements. This does not hold true with patients suffering conditions like fever, cough, diarrhea, and myalgia/fatigue.

For evaluation of publication bias in the article in the meta-analysis, we employed the R meta-package for visualization of the funnel plots. The outcomes of publication bias are shown in Figs. 5 and 6.

Fig. 5: Publication bias funnel plots for diabetes mellitus, hypertension, coronary heart disease, and cardiovascular disease.

Fig. 6: Publication bias funnel plots for respiratory failure/ ARDS, dyspnea, and chest tightness/pain

This analysis employed the seven-machine learning/feature selection techniques outlined in the methodology section indicating that diabetes was listed in the top 10 crucial attributes for 6 techniques, and then heart (5/7), hypertension (4/7), and COPD (4/7). Clinical conditions like cough (6/7), fever (5/7), chest pain (4/7), and fatigue (4/7) are similarly listed in the top 10 important attributes.

Conclusion/discussion

This research has offered a comprehensive vision review/meta-analysis regarding the influence of comorbidities, e.g. diabetes and hypertension, on the severity of COVID-19. The meta-analysis employed data gathered from 12 studies covering the 4101 patients in Chinese hospitals with a COVID-19 diagnosis confirmed by laboratory. Patients from the severe group were all higher age (median age 58.8) than the patients in the non-severe group (median age 48.5). There were more males than females in the study (2196 males, 1702 females). Two of the studies (21 and 24) indicated a significant correlation between gender and disease severity. Every study examined agreed that being female has no significant correlation with disease severity (OR 0.74; 95% CI: 0.61-0.89); rather, as with SARS-CoV and MERS-CoV patients [26], there is simply a greater likelihood of infection for males as they generally have higher exposure levels.

Meta-analysis of comorbidity found that diabetes mellitus (11.34%) and hypertension (22.07%) are two of the most prevalent conditions in this patient cohort; this almost exactly parallels the levels of hypertension and diabetes amongst the population of China as a whole (hypertension 23.2% [27], diabetes mellitus 10.9% [28]).

Meta-analysis also demonstrated that unfavourable outcomes had significant associations with diabetes (OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), hypertension (OR 2.43 [95% CI: 1.71-3.45], p < 0.0001)), coronary heart disease (OR 2.97 [95% CI: 1.99-4.45], p < 0.0001), cardiovascular disease (OR 2.89 [95% CI: 1.90-4.40], p < 0.0001), and COPD (OR 3.24 [95% CI: 1.66-6.32], p = 0.0006). Fang L et al [29] found that human pathogenic coronaviruses, e.g. SARS-CoV and SARS-CoV-2 achieve binding with target cells using Angiotensin-Converting Enzyme 2 (ACE2), which originates from epithelial cells in the blood vessels, kidneys, intestines, and lungs [30]. ACE2 levels are considerably higher for patients suffering type I or type II diabetes; because of this they are given treatment with ACE inhibitors and/or Angiotensin II type-1 Receptor Blockers (ARBs). These medications are also used in the treatment of hypertension, and this causes an upregulation of ACE2 [31]. ACE2 may also be increased using either ibuprofen or thiazolidinediones. Higher levels of ACE2 would therefore promote COVID-19 infection. Thus we agree with the hypothesis that treating hypertension or diabetes with ACE2-stimulators could predispose patients to more severe COVID-19. We thus concur with Fang et al [29] that patients with diabetes, hypertension, or cardiac disease being medicated with ACE2-increasing medication must be regarded as having a greater risk of developing severe COVID-19 and so they should be closely monitored for the effects of self-medication.

Zhao Q et al, in a recent review [32] found that extant COPD makes it four times more likely that severe COVID-19 will develop. These authors also examine the influence of smoking in COVID-19 severity, coming to the conclusion that there is no significant correlation. This accords with the findings of this meta-analysis. There has always been an assumption that smoking may have an association with less favorable disease outcomes, as there is copious research regarding the detrimental effects of smoking on lung health and the causal correlation between it and many different forms of respiratory disease [33]. Furthermore, smoking is injurious to the immune system and the body's ability to respond to infection, which means that smokers are more susceptible to contracting infections [34]. This accords with this paper's meta-analysis, although, as Lippi G and Henry BM [35] indicate, more research will be necessary as further evidence becomes available; from the limited data available at present, and while acknowledging that the findings above have not been adjusted for other elements that may influence the disease pathway, it seems probable that smoking has a correlation with more severe undesirable outcomes in COVID-19 cases.

While patients exhibiting abnormal liver results are regarded as being significantly more likely to develop severe pneumonia, and employing ritonavir or lopinavir makes patients four times more likely to suffer liver injury [36], this meta-analysis did not find a significant correlation between liver disease and negative outcomes. This accords with recent research from [37], which stated that while it is common for COVID-19 patients to exhibit abnormal liver function index, this is not a significant factor in COVID-19 patients, and it may not be associated with serious negative clinical outcomes.

The study by Guan W et al [19] was the only one of the 12 articles under review that found a significant correlation between kidney disease and COVID-19 severity; examining the articles in total, no significant correlation is found (p = 0.0476). The clinical symptoms that are most frequently exhibited are fever (74.52%), cough (62.15%), myalgia/fatigue (38.7%), dyspnoea (33.9%), respiratory failure/ARDS (20.6%), diarrhea (11.21%), and chest tightness/pain (16.82%). This accords with the majority of published research. In terms of heterogeneity, in the majority of cases zero or low heterogeneity was displayed by the I^2, so there is relative homogeneity in the majority of cases examined for this research.

This meta-analysis has certain limitations that could be mitigated in future research: firstly, only patients in Chinese hospitals were included in the studies under review, and generalisability can only be assumed if research including other populations is incorporated; secondly, the presence of multiple comorbidities in single patients has not been considered (this is an element virtually every other review as overlooked also); finally, this meta-analysis does not encompass laboratory, radiographic, clinical, or demographic data.

Acknowledgment:
The authors would like to thank Mr. Dwight Gunning for his kind assistance with the search engine.

Conflict of interest:
The authors declare no conflict of interest.

Authors Contributions:

NZ and EA performed the the literature scan and review, NZ performed the meta-analysis, all authors contributed to the paper writing, GK and SI validated the findings.

References

[1] Zaki N., Mohamed EA., "The estimations of the COVID-19 incubation period: a systematic review of the literature," *medRxiv,* 2020.

[2] WHO, "Coronavirus disease (COVID-19) Pandemic," *World Health Organization,* 2020.

[3] Burki TK., "Cancer care in the time of COVID-19," *The Lancet,* vol. 21, 2020.

[4] Zhou F., Yu T., Du R., Fan G., Liu Y., et al. , "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study," *The Lancet,* p. 1054–1062, 2020.

[5] Wang LL. and Lo K., Chandrasekhar Y., Reas R., Yang J. et. al., "CORD-19: The Covid-19 Open Research Dataset," *ArXiv,* vol. abs/2004.10706, 2020.

[6] Manning CD., Raghavan P., Schütze H., An Introduction to Information Retrieval, Cambridge, UK: Cambridge University Press, 2009.

[7] Bernhardsson E., "Annoy," [Online]. Available: https://github.com/spotify/annoy.

[8] Shevade S.K., Keerthi S.S., Bhattacharyya C., Murthy K.R.K., "Improvements to the SMO Algorithm for SVM Regression," *IEEE Transactions on Neural Networks,* vol. 11, no. 5, 2000.

[9] Hornik K., HalbertWhite, MS., "Multilayer feedforward networks are universal approximators," *Neural Networks,* vol. 2, no. 5, pp. 359-366, 1989.

[10] Breiman L., "Random Forests," *Machine Learning,* vol. 45, p. 5–32, 2001.

[11] Kohavi R., John GH., "Wrappers for feature subset selection," *Artificial Intelligence,* vol. 97, pp. 273-324, 1997.

[12] Kira K., Rendell LA., "Practical Approach to Feature Selection," in *9th International Workshop on Machine Learning*, 1992.

[13] Frank E., Hall MA., and Witten IH., he WEKA Workbench. Online Appendix for "Data Mining: Practical Machine Learning Tools and Techniques, 4, Ed., Morgan Kaufmann, 2016.

[14] Liu W., Tao Z., Wang L., Yuan M., Liu K., et al. , "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease," *Chinese Medical Journal,* 2020.

[15] Huang C., Wang Y., Li X., Ren L., Zhao J., et al., "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China," *The Lancet,* vol. 395, 2020.

[16] Wang D., Hu B., Hu C., Zhu F., Liu X., et al. , "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China," *JAMA,* vol. 323, no. 11, 2020.

[17] Tian J., Yuan X., Xiao J., Zhong Q., Yang C., et al., "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study," *The Lancet,* 2020.

[18] Zhang JJ., Dong X., Cao YY., et al., "Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China," *Allergy,* 2020.

[19] Guan W., Ni Z., Hu Y., et al., "Clinical characteristics of coronavirus disease 2019 in China," *N Engl J Med,* 2020.

[20] Zhang J., Wang X., Jia X., Li L., Hu K., et al. , "Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China," *Clinical Microbiology and Infection,* vol. 26, pp. 767-772, 2020.

[21] Li X., Xu S., Yu M., Wang K., Tao Y., et al., "Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan," *J. Allergy Clin. Immunol.,* 2020.

[22] Zheng F., Tang W., Li H., Huang YX., Xie YL., et al. , "Clinical characteristics of 161 cases of coronavirus disease 2019 (COVID-19) in Changsha," *European Review for Medical and Pharmacological Sciences,* vol. 24, pp. 3404-3410, 2020.

[23] Feng Y., Ling Y., Bai T., Xie Y., Huang J., et al., "COVID-19 with Different Severities: A Multicenter Study of Clinical Features," *American Journal of Respiratory and Critical Care Medicine,* vol. 201, no. 11, 2020.

[24] Shi Y., Yu X., Zhao H., Wang H., Zhao R., et al., "Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan," *Critical Care,* vol. 24, no. 108, 2020.

[25] Huang R., Zhu L., Xue L., Liu L., Yan X., et al., "Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study," *PLoS Negl Trop Dis.,* vol. 14, no. 5, 2020.

[26] Channappanavar R., Fett C., Mack M., Ten Eyck P., Meyerholz DK., Perlman S., "Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection," *J Immunol,* vol. 198, no. 10, pp. 4046-4053, 2017.

[27] Hu S., Gao R., Liu L., Zhu M., Wang W., Wang Y., et al. , "Summary of the 2018 report on cardiovascular diseases in China," *Chin Circ J.,* vol. 39, no. 209, 2019.

[28] Liu Y., Yang Y., Zhang C., Huang F., Wang F., et al., "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury," *Science China Life Sciences,* vol. 63, p. 64–374, 2020.

[29] Fang L., Karakiulakis G., Rotha M., "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?," *Lancet Respir Med.,* vol. 8, no. 4, p. e21, 2020.

[30] Wan Y., Shang J., Graham R., Baric RS., Li F., "Receptor recognition by novel coronavirus from Wuhan: an analysis based on decadelong structural studies of SARS.," *J Virology,* 2020.

[31] Li XC., Zhang J., Zhuo JL. , "The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.," *Pharmacol Res,* vol. 125, p. 21–38, 2017.

[32] Zhao Q., Meng M., Kumar R., Wu Y., Huang J., et al., "The impact of COPD and smoking history on the severity of COVID-19 A systemic review and meta-analysis," *Journal of Medical Virology,* 2020.

[33] Tonnesen P., Marott JL., Nordestgaard B., Bojesen SE., Lange P., "Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study," *Tob Induc Dis.,* 2019.

[34] Zhou Z., Chen P., Peng H., "Are healthy smokers really healthy?," *Tob Induc Dis.,* vol. 14, no. 35, 2016.

[35] Lippi G., Henry BM., "Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)," *Eur J Intern Med,* vol. 75, pp. 107-108, 2020.

[36] Fan Z., Chen L., XinCheng J., Yang J., Tian C., et al. , "Clinical Features of COVID-19-Related Liver Functional

Abnormality," *Clinical Gastroenterology and Hepatology,* vol. 18, no. 7, pp. 1561-1566, 2020.

[37] Zhang Y., Zheng L., Liu L., Zhao M., Xiao J., Zhao Q., "Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China," *Liver International,* 2020.